MALDI BIOTYPER CA (MBT-CA) SYSTEM

by BRUKER DALTONICS  · Based in United States → — Rapid, Accurate, and Reliable Microbial Identification for Clinical Diagnostics
Infectious Disease Laboratory Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing
Regulatory Status Disclosed

Overview

The Bruker MALDI Biotyper CA (MBT-CA) System is a qualitative in vitro diagnostic mass spectrometer system that utilizes Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometry technology. It is designed for the rapid, accurate, and reliable identification of microorganisms, including Gram-negative bacteria, Gram-positive bacteria, anaerobes, and yeasts, cultured from human specimens. The system measures a unique proteomic fingerprint of an organism and compares it against an extensive FDA-cleared reference library to provide identification within minutes. It is intended for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of microbial infections. The MBT-CA System is a robust, benchtop solution optimized for efficient workflow and high-throughput capabilities in clinical microbiology laboratories.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • MALDI-TOF mass spectrometry technology for microbial identification
  • Rapid microorganism identification (results within minutes)
  • Extensive FDA-cleared reference library (currently 549 clinically validated species)
  • High accuracy, comparable to 16S rRNA gene sequencing
  • Streamlined and easy-to-use workflow requiring minimal mass spectrometry experience
  • Automated mass spectrum acquisition and database matching
  • Clear result interpretation with a 'traffic light' color scheme
  • High throughput capability (e.g., 96 sample positions, up to 192 samples/hour for previous generation, 600 samples/hour for sirius one)
  • Identification from isolated colonies and positive blood cultures
  • Software supports 21 CFR Part 11 compliance for electronic records

Use Cases

  • Identification of Gram-negative bacterial infections
  • Identification of Gram-positive bacteria, anaerobes, and yeasts
  • Routine use in clinical microbiology laboratories
  • Rapid diagnosis of bloodstream infections and sepsis
  • Aiding in the diagnosis of microbial infections in conjunction with other clinical and laboratory findings

What Physicians Need to Know

LIS/LIMS Integration
Supports seamless integration with Laboratory Information Systems (LIS) and Laboratory Information Management Systems (LIMS) for both import and export of data. It utilizes CSV files and ASTM sockets for data exchange, with the MBT Server managing all integration. A customizable smart translation tool converts species names for compatibility with LIS, expert systems, or AST systems.
Supported Assay Types
A qualitative in vitro diagnostic mass spectrometry system for the identification of a broad range of microorganisms. It identifies Gram-negative bacteria, Gram-positive bacteria, anaerobes, and yeasts cultured from human specimens, including isolated colonies and directly from positive blood cultures using the MBT Sepsityper IVD Kit.
QC/QA Features
Features automatic calibration using the US IVD Bacterial Test Standard (BTS) before each use to ensure system readiness. The MBT Compass HT CA software includes IDealTune, an automated tuning function that continuously monitors quality control results to maintain optimal system performance and reduce manual adjustments.
Result Interpretation AI
Employs a sophisticated biostatistical algorithm to compare the mass spectrum of an unknown organism against an extensive FDA-cleared reference database. It generates a log(score) value (0.00-3.00) to indicate the degree of similarity, with scores u2265 2.00 signifying high confidence for species-level identification. Results are presented in an easy-to-interpret 'traffic light' color scheme.
Critical Value Alerts
While direct 'critical value alerts' are not explicitly detailed as a software feature, the system's rapid identification capabilities and LIS integration facilitate prompt communication of results, enabling laboratories to quickly relay critical findings to clinicians.
Instrument Interfaces
The core instrument is the microflex LT/SH mass spectrometer. It interfaces with dedicated microbiology software, such as MBT Compass HT CA, which automates mass spectra acquisition and database matching. It also integrates with flexControl software for automated acquisition processes.
Reference Range Intelligence
Utilizes an extensive FDA-cleared reference library of Main Spectra (MSP) for microorganism identification. This library has been significantly expanded to encompass 549 clinically validated microbial species across Gram-positive and Gram-negative bacteria, anaerobes, and yeasts. The database is built from multiple measurements of defined strains to ensure comprehensive biological variability capture. Non-clinically validated species are clearly marked and cannot be transmitted to the LIS.
Turnaround Time Impact
Dramatically reduces the turnaround time (TAT) for microbial identification from days to minutes compared to traditional methods. This rapid identification, including results from positive blood cultures in under 30 minutes, enables quicker clinical decisions and helps in the timely initiation of appropriate antibiotic therapy.
Microbiology ID Support
Provides highly accurate microorganism identification by analyzing unique molecular (proteomic) fingerprints using MALDI-TOF mass spectrometry. The system offers identification down to the species level with accuracy comparable to 16S rRNA gene sequencing.
Physician Tip

The MALDI Biotyper CA System offers rapid and highly accurate microbial identification, which is crucial for timely diagnosis and effective patient management, especially in cases of bloodstream infections and sepsis. The quick turnaround time can significantly reduce the time to optimal antibiotic therapy, potentially improving patient outcomes and reducing ICU stays. Physicians should be aware that results for non-clinically validated organisms, though identified by the system, will not be automatically transmitted to the LIS, requiring alternative laboratory methods for confirmation.

The system's robust LIS/LIMS integration capabilities, supporting CSV and ASTM formats, allow for streamlined data flow within the laboratory informatics ecosystem. The customizable smart translation tool is key for ensuring compatibility with various downstream systems like expert systems and AST platforms. This connectivity is vital for maximizing laboratory efficiency and ensuring that rapid identification results are seamlessly incorporated into patient records and clinical decision support systems.

Details

Category Lab & Diagnostics
Pricing Contact vendor for pricing
DeploymentOn-premise (benchtop instrument)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The MALDI Biotyper CA System received initial FDA 510(k) clearance (K130831) on November 21, 2013, for the identification of Gram-negative bacterial colonies cultured from human specimens. Subsequent clearances expanded its capabilities to include Gram-positive bacteria, anaerobes, and yeasts, with the latest expansion covering 549 clinically validated microbial species.
Integrations
EHR Not specified
Specialties Infectious Disease, Laboratory Medicine

What the Web Says

The Bruker MALDI Biotyper CA (MBT-CA) System is a mass spectrometry-based in vitro diagnostic device used for rapid and accurate identification of microorganisms, including bacteria and yeasts, from cultured human specimens. It has been evaluated in multicenter studies and received FDA clearance for an expanding library of microbial species. The system is highly regarded for its speed, ease of use, and cost-effectiveness in clinical microbiology laboratories.

Overall: Positive

Strengths

  • Rapid identification of microorganisms within minutes.
  • High accuracy in identifying clinically important bacteria and yeasts, with high-confidence results comparable to 16S rRNA gene sequencing.
  • Cost-effective per identification compared to traditional methods.
  • Streamlined and efficient workflow, requiring minimal hands-on time and simple steps.
  • Extensive and expanding FDA-cleared reference library covering a wide range of microbial species.
  • Can combine routine and positive blood culture specimens in one run, saving time and costs.

Limitations

  • May have difficulty differentiating between closely related species, requiring supplemental testing in some cases.
  • Performance can be decreased for certain difficult-to-differentiate species, such as *Haemophilus haemolyticus* from *H. influenzae*.
  • Some isolates may not produce acceptable confidence scores, requiring alternative identification methods.
  • Requires costly infrastructure and expert personnel for ML-assisted diagnostics, though MALDI-TOF MS itself is relatively inexpensive.
  • Limited information on its ability to determine antimicrobial resistance on its own.

Based on reviews from: Multicenter Evaluation of the Bruker MALDI Biotyper CA System for the Identification of Clinical Aerobic Gram-Negative Bacterial Isolates - PMC, Multicenter Evaluation of the Bruker MALDI Biotyper CA System for the Identification of Clinical Aerobic Gram-Negative Bacterial Isolates - Research journals - PLOS, Using Machine Learning to Predict Antimicrobial Resistanceu2015A Literature Review, Multicenter Evaluation of the Bruker MALDI Biotyper CA System for the Identification of Clinically Important Bacteria and Yeasts - PubMed, BDu2122 Bruker MALDI Biotyperu00ae CA System, Buy MALDI Biotyperu00ae sirius System Read Reviews - Select Science, Multicenter Evaluation of the Bruker MALDI Biotyper CA System for the Identification of Clinically Important Bacteria and Yeasts - Oxford Academic, Using Machine Learning to Predict Antimicrobial Resistanceu2015A Literature Review - Semantic Scholar, Using Machine Learning to Predict Antimicrobial Resistanceu2015A Literature Review - PMC, Benefits and Limitations of MALDI-TOF Mass Spectrometry for the Identification of Microorganisms - Journal of Infectiology and Epidemiology, (PDF) Performance and workflow comparison of the VITEK MS PRIME and Bruker Biotyper MALDI-TOF MS systems - ResearchGate, Rapid Antibiotic Susceptibility Testing by Deuterium Labeling of Bacterial Lipids in On-Target Microdroplet Cultures | Journal of the American Society for Mass Spectrometry - ACS Publications, bacterial dna extraction: Topics by Science.gov, Bruker Announces US FDA Clearance of Expanded 3rd Claim for MALDI Biotyper, Using Machine Learning to Predict Antimicrobial Resistanceu2015A Literature Review - MDPI, [PDF] Optimization of Routine Identification of Clinically Relevant ..., Bruker Announces US FDA Clearance of Expanded 3rd Claim for MALDI Biotyper, Experimental Validation of Comprehensive Calculation for High-Resolution Linear MALDI-TOF Mass Spectrometry - ACS Publications, coryneform bacterial isolates: Topics by Science.gov, bacterial isolates representing: Topics by Science.gov, gram-negative bacterial endotoxin: Topics by Science.gov, K163536.pdf - accessdata.fda.gov, HILIC-IM-MS for Simultaneous Lipid and Metabolite Profiling of Bacteria | ACS Measurement Science Au

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate MALDI BIOTYPER CA (MBT-CA) SYSTEM

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Bruker Corporation
Bruker Announces US FDA Clearance of Expanded 3rd Claim for MALDI Biotyper
Bruker received US FDA clearance for its third, expanded claim for the MALDI Biotyper-CA (MBT-CA) system, significantly increasing its microbial reference library to 424 species for clinical microbiology. The clearance also includes new disposable MBT Biotargets 96 US IVD with AnchorChipu2122 technology for improved workflow and cost-efficiency.
2017-07
Journal of Infectiology and Epidemiology
Benefits and Limitations of MALDI-TOF Mass Spectrometry for the Identification of Microorganisms
This article discusses the benefits and limitations of MALDI-TOF MS, including the MALDI Biotyper CA (MBT-CA) System, for identifying microorganisms in clinical laboratories. It highlights the technology's ability to provide timely and accurate identification but notes limitations with inherently similar organisms or a limited database.
2019-07
PMC (PubMed Central)
Multicenter Evaluation of the Bruker MALDI Biotyper CA System for the Identification of Clinical Aerobic Gram-Negative Bacterial Isolates
This study evaluated the MALDI Biotyper CA (MBT-CA) System for identifying aerobic gram-negative bacteria as part of a 510(k) submission to the FDA, demonstrating high accuracy in identifying 99.8% to genus and 98.2% to species level.
2015-11
FDA
510(k) Premarket Notification - MALDI BIOTYPER CA (MBT-CA) SYSTEM
This FDA document is a 510(k) Premarket Notification for the MALDI BIOTYPER CA (MBT-CA) SYSTEM by Bruker Daltonics, Inc., classifying it as a qualitative in vitro diagnostic mass spectrometer system for identifying Gram-negative bacterial colonies.
2015-03
FDA
510(k) Premarket Notification - MALDI Biotyper CA (MBT-CA) System, MBT smart CA System
This FDA 510(k) Premarket Notification pertains to the MALDI Biotyper CA (MBT-CA) System and MBT smart CA System from Bruker Daltonik GmbH.
2017-07
MDPI
Using Machine Learning to Predict Antimicrobial Resistanceu2014A Literature Review
This review mentions the MALDI Biotyper CA (MBT-CA) System as an FDA-approved MALDI algorithm for microorganism identification, highlighting its role in the context of machine learning applications for predicting antimicrobial resistance.
2023-02
Journal of the American Society for Mass Spectrometry
Rapid Antibiotic Susceptibility Testing by Deuterium Labeling of Bacterial Lipids in On-Target Microdroplet Cultures
This research article discusses the use of MALDI-TOF systems, such as the MALDI Biotyper, for bacterial identification and explores new methods for rapid antibiotic susceptibility testing using deuterium labeling, aiming to overcome the limitations of current systems in providing resistance information.
2022-05
ACS Measurement Science Au
HILIC-IM-MS for Simultaneous Lipid and Metabolite Profiling of Bacteria
This article discusses the limitations of protein-centric MALDI-ToF platforms, including the MALDI Biotyper CA (MBT-CA) System, for discriminating closely related species and detecting antimicrobial resistance, proposing alternative mass spectrometry-based methods like lipid and metabolite profiling.
2023-12

Videos

Product demos, reviews, and walkthroughs for MALDI BIOTYPER CA (MBT-CA) SYSTEM.

View all on YouTube

Frequently Asked Questions

The MBT-CA system utilizes MALDI-TOF mass spectrometry to rapidly identify microorganisms by analyzing their unique protein fingerprints and comparing them against an extensive FDA-cleared database. This technology significantly reduces turnaround time for pathogen identification, aiding in the diagnosis of bacterial infections and supporting timely antibiotic stewardship decisions in clinical settings. While the core identification relies on mass spectrometry and database matching, Bruker is actively exploring AI-driven applications for advanced analytics, such as antibiotic resistance prediction.
The MALDI Biotyper CA System has received FDA clearance for clinical microbial identification, with its software supporting 21 CFR Part 11 compliance, which is crucial for electronic records in healthcare. Bruker regularly expands its FDA-cleared reference library, which now includes 549 clinically validated microbial species. The system ensures data integrity through features like improved user management and automated tuning functions that maintain consistent diagnostic reliability.
Primary alternatives to MALDI-TOF systems like MBT-CA include genetic sequencing, such as 16S rRNA gene sequencing and whole-genome sequencing, and traditional biochemical testing. While genetic sequencing is highly accurate and considered a gold standard, MALDI-TOF offers significantly faster results and is generally more cost-effective per sample. Traditional biochemical methods are slower, more labor-intensive, and often lack the discriminatory power of MALDI-TOF.
The cost of implementing the MBT-CA system includes the initial purchase of the instrument, which can be substantial, along with ongoing expenses for consumables. These consumables typically include disposable target plates, such as the MBT Biotarget 96, and reagents like the HCCA matrix and Bacterial Test Standards. While specific AI software licensing fees for core identification are not typically itemized separately, the system's overall cost-effectiveness is often cited due to its speed and reduced labor requirements.
While highly accurate, the MBT-CA system's diagnostic accuracy is dependent on its reference database and may struggle to differentiate between very closely related species, such as *Escherichia coli* and *Shigella*. The system also requires organisms to be cultured first, which can still take approximately 18 hours. Although the current system primarily uses database matching rather than explicit AI for identification, any future integration of AI for applications like antimicrobial susceptibility testing could potentially introduce biases if the training data is not diverse or representative.
The MBT-CA system is designed for seamless integration with existing laboratory information systems (LIS) and electronic health records (EHR) through dedicated data management platforms like BD EpiCenteru2122 and BD Synapsysu2122 Informatics Solution. This connectivity facilitates the automatic transfer of microbial identification results, streamlining workflow and ensuring timely communication of critical microbiology data to clinicians. Such robust data flow is essential for future AI-driven insights, enabling comprehensive analysis and reporting across patient care systems.
The MBT-CA system is designed for user-friendliness, with a streamlined workflow that typically requires minimal prior mass spectrometry experience for basic operation. Its dedicated software automates spectrum acquisition and database matching, presenting results with an easy-to-interpret 'traffic light' color scheme. However, interpreting results for organisms with lower confidence scores or in the context of emerging AI-driven applications for resistance prediction still necessitates review and expertise from trained microbiologists to ensure accurate clinical decisions.

Related Tools

DeepMind (Google)
Google DeepMind
Clinical Decision Support & Reference
AlphaFold is an AI system developed by DeepMind (Google) that accurately predicts protein structures and their interactions, significantly accelerating biological and medical research.
Free for non-commercial use
Tempus AI
Tempus AI
Clinical Decision Support & Reference
Tempus ECG-AI Platform uses artificial intelligence to analyze electrocardiogram data, offering advanced insights for cardiovascular diagnosis and management.
LabLynx AI-Powered LIMS
LabLynx
Lab & Diagnostics
LabLynx AI-Powered LIMS integrates AI and Machine Learning into laboratory information management systems to automate complex analyses, predict outcomes, and optimize workflows for various lab settings. The platform offers LIMS, ELN, and Lab Automation suites, providing configurable and scalable solutions for diverse laboratory needs.
August AI
August AI
Lab & Diagnostics
August AI offers an AI-enabled telehealth platform with an AI health chatbot and virtual care services, including telehealth visits and prescription management. The company's AI chatbot is available globally for free, providing information and not medical advice. In the U.S., August AI offers August Care, a membership that provides clinical services, discounted labs, and quick prescriptions.
$0 (chatbot) / $39 per visit / $39 per month (august care membership)
Allergios®
Allergios®
Lab & Diagnostics
Allergios® is developing an in-vitro diagnostic system that directly visualizes allergic responses in blood serum to provide unambiguous allergy diagnoses, starting with food allergies.
PNOĒ
PNOĒ
Endocrinology & Metabolic AI
PNOĒ is a science-backed cardiometabolic analyzer that performs comprehensive breath-based assessments to measure 23 biomarkers, including VO₂ max, resting metabolic rate (RMR), fat burn efficiency, and biological age. It delivers a 360° snapshot of an individual's physiology by analyzing how oxygen flows through the lungs, heart, and cells. The insights generated are used to personalize nutrition, exercise, and longevity plans.
Varies

See all Lab & Diagnostics tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.